Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cyclerion Therapeutics, Inc. (CYCN)
|
Add to portfolio |
|
|
|
| Price: |
$1.77
| | Metrics |
| OS: |
43.5
|
M
| |
-463
|
% ROE
|
| Market cap: |
$77
|
M
| |
|
|
|
Net cash:
|
$13.4
|
M
| |
$0.31
|
per share
|
|
EV:
|
$63.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($51.8)
|
M
| |
|
|
|
EBIT
|
($52.0)
|
M
| |
|
|
| EPS |
($1.14)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 1.6 | 3.9 | 2.3 | 4.5 | 0.0 | 78.8 |
| Revenue growth | -58.8% | 71.7% | -49.1% | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 78.8 |
| Gross profit | 1.6 | 3.9 | 2.3 | 4.5 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | | 0.0% |
| Selling, general and administrative | | | 83.6 | | | |
| Research and development | 31.5 | 37.6 | | 95.1 | 87.7 | |
| General and administrative | 14.5 | 20.6 | | 34.4 | 27.5 | 15.1 |
| EBIT | -44.4 | -55.2 | -121.8 | -125.0 | -115.3 | -93.9 |
| EBIT margin | -2730.6% | -1400.2% | -5305.7% | -2774.3% | | -119.2% |
| Pre-tax income | -44.1 | -51.6 | -122.4 | -122.4 | -115.3 | -93.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% |
| Net income | -44.1 | -51.6 | -77.8 | -123.0 | -115.3 | -93.9 |
| Net margin | -2712.5% | -1310.2% | -3388.6% | -2729.3% | | -119.2% |
| |
| Diluted EPS | ($1.01) | ($1.32) | ($2.56) | ($4.49) | ($4.21) | |
| Shares outstanding (diluted) | 43.5 | 39.1 | 30.4 | 27.4 | 27.4 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|